Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. Sugar Land, Texas, 1 NOV 2024: Hope Biosciences, a clinical-stage biotechnology company that manufactures mesenchymal stem cell therapeutics through proprietary technology unprecedented in its ability to create repeatable treatments, today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting mu

By Jan Shultis, Ph.D. At Hope Biosciences, our love language is stewardship (cliché, perhaps, but true!). Some days that stewardship is grittier than others, like it was earlier this summer, when Hurricane Beryl blasted through Houston. A Category 1 hurricane, the storm resulted in extreme loss of vegetation, complicating restoration of electricity after it moved through the area. Most of the business, community, and personal losses attributed to the storm resulted from lack

By Jan Shultis, Ph.D. The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Worried about tomorrow’s workforce? Stay away from negative mainstream media and listen to us! Hope Biosciences welcomed a busload of college students for a work-focused visit earlier this month. After great conversations, we are delighted to report that if these young men and women are indicative of years to come, the future of healthcare is in good hands. On Tuesday, Jun